Trained on 9.7 trillion tokens of evolutionary data, EDEN designs therapeutics from large gene insertion to antimicrobial peptides.
The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback